<PAGE>
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported) June 20, 1996
--------------
CORTEX PHARMACEUTICALS, INC.
------------------------------------------------------
(Exact name of registrant as specified in its charter)
Delaware 0-17951 33-0303583
---------------------------------------------------------------
(State or other jurisdiction (Commission (IRS Employer
of incorporation) File Number) Identification No)
15241 Barranca Parkway, Irvine, California 92718
---------------------------------------------------------------
(Address of principal executive offices) (Zip Code)
Registrant's telephone number, including area code (714) 727-3157
--------------
Not Applicable
-----------------------------------------------------------------
(Former name or former address, if changed since last report)
Page 1 of 4
Exhibit Index on Page 3
<PAGE>
ITEM 5. OTHER EVENTS
On June 20, 1996, Cortex Pharmaceuticals, Inc. (the "Company") announced
its intention to make a private placement of its Common Stock. The Company
intends to raise $7 to $10 million in a private placement of common stock to
accredited individual and institutional investors pursuant to Regulation D under
the Securities Act of 1933, as amended. The Company said that it intends to use
the proceeds for research and development, including the further clinical
development of its AMPAKINE-TM- compounds for the potential treatment of
Alzheimer's disease and schizophrenia, and for general corporate working capital
purposes. No other terms were disclosed.
ITEM 6. EXHIBITS
Exhibits:
21 Press Release dated June 20, 1996.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned thereunto duly authorized.
CORTEX PHARMACEUTICALS, INC.
Date: June 26, 1996 By: /s/D. Scott Hagen
-----------------------------------------------
D. Scott Hagen
Vice President and Chief Financial Officer
2
<PAGE>
EXHIBIT INDEX
Sequential
Exhibits Description Page No.
-------- ----------- --------
21 Press release dated 4
June 20, 1996
3
